Cell and gene therapies require novel quality control methods due to their complex, variable nature and limited shelf life, challenging traditional pharmaceutical testing approaches. Manufacturers ...

The AI and HPC industries are rapidly shifting toward chiplet-based designs to achieve unprecedented levels of performance, as traditional monolithic system-on-chip (SoC) architectures face scaling ...